Evidence map›Paper›PMID 37474164›Full record

ArticleBMJ open2023

Higher risk of future events, mortality and greater healthcare use among patients with increasingly recurrent atherosclerotic cardiovascular disease events in Taiwan: a retrospective cohort study.

Chia-Yun Hsu, Wen-Jone Chen, Hung-Ju Lin, Ho-Min Chen, Yea-Harn Yang, Wei-Ju Chen, Chieh-Min Chen, Fei-Yuan Hsiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chia-Yun HsuHealth Data Research Center, National Taiwan University, Taipei, Taiwan.
Wen-Jone ChenDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-2098-5922
Hung-Ju LinDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Ho-Min ChenHealth Data Research Center, National Taiwan University, Taipei, Taiwan.
Yea-Harn YangAmgen Taiwan Limited, Taipei, Taiwan.
Wei-Ju ChenAmgen Taiwan Limited, Taipei, Taiwan.
Chieh-Min ChenGraduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Fei-Yuan HsiaoGraduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan fyshsiao@ntu.edu.tw.ORCID 0000-0003-1660-9120
National Taiwan University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe the occurrence of recurrent atherosclerotic cardiovascular disease (ASCVD) events within 3 years after a new-onset event, the associated disease burden and statin prescribing in patients with ASCVD in Taiwan.

designRetrospective cohort study.

settingThis was a retrospective cohort study using Taiwan's National Health Insurance Research Database.

participantsIn total, 111 399, 133 538 and 21 572 patients who were hospitalised with diagnosis of coronary heart disease (CHD), cerebrovascular disease (CBVD) and peripheral artery disease (PAD), respectively, between 1 January 2012 and 31 December 2014. PRIMARY AND SECONDARY OUTCOME MEASURES: For each index and recurrent event, patients were observed for 12 months after admission to quantify risks of mortality, recurrent events, statin treatment and healthcare use.

resultsWe identified 97 321, 120 914 and 14 794 patients with new-onset CHD, CBVD and PAD, respectively. The proportions of developing first, second and third recurrent events were 22.5%, 25.6% and 30.9% for CHD; 20.9%, 26.2% and 32.4% for CBVD and 40.2%, 41.4% and 43.6% for PAD, respectively. Most patients had the same type of ASCVD for their recurrent events as their new-onset event. The mortality rates increased with each recurrent event (p<0.05 for all three ASCVD groups). The rates of hospital readmission and emergency room (ER) visit increased with increasing recurrent events. For example, in the CHD group, the 1-year readmission rates following the index, first and second recurrent events were 43.1%, 47.6% and 55.3%, respectively, and the proportions of visiting ER were 46.4%, 51.9% and 57.8%, respectively. Statin prescribing was suboptimal at time of index event and recurrent events.

conclusionRecurrent ASCVD events were associated with a higher risk of recurrent event and mortality and greater healthcare use. However, statin prescriptions at index event and after each recurrent event were suboptimal.

Indexed as

AtherosclerosisCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsDelivery of Health CareHumansRetrospective StudiesRisk FactorsTaiwanHydroxymethylglutaryl-CoA Reductase Inhibitorscardiac epidemiologycoronary heart diseaseepidemiology

Identifiers

PMID37474164
PMCPMC10357687
OpenAlexW4384924689

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.